The differences of scFv and nanobody in structure.
DOI: 10.1186/s40364-021-00332-6
Antibody engineering has significantly advanced with the development of various formats that enhance therapeutic efficacy and diagnostic precision. Single-chain variable fragments (scFvs) represent one of these innovative formats. Consisting only of the variable regions of the heavy (VH) and light (VL) chains of immunoglobulins linked by a short peptide, scFvs maintain the antigen-binding ability of the parent antibody. Being 25-30 kDa in size, they are significantly smaller than a full antibody. The design of the linker is critical as it influences the stability and the binding affinity of the scFv.
scFvs were first conceptualized and developed in the late 1980s as researchers sought to create more manageable antibody fragments for therapeutic use. These fragments were designed to overcome the limitations posed by the size and complexity of conventional monoclonal antibodies, making them suitable for applications where size and penetration into tissues are crucial.
Timeline
1988: A paper by Huston et al. demonstrated the design of an engineered scFv with a single polypeptide connected with a 15 amino acid linker. It showed clear specificity against digoxin, with recovery of activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.1
1990s: Refinement of scFv technology addressed issues such as stability and solubility. There was also increasing interest in potential applications in diagnostics and therapeutics. Cheadle et al. cloned and expressed the Fv portion of a mouse myeloma protein, which was found to be biologically active with an identical affinity as that of the native Fv.2
Early 2000s: Growing use of scFvs in diagnostic applications, including immunoassays and imaging, in addition to therapeutic purposes, especially in cancer targeting.
Mid-2000s: Introduction of bispecific scFvs, capable of binding two different antigens simultaneously.
2010s - Present: scFvs began entering clinical trials for therapeutic applications, with ongoing research to improve stability, bioavailability, and reduce potential immunogenicity.
Altogether, scFvs have gained significant importance with applications spanning preclinical, clinical, and research domains. Progress in antibody engineering has enabled the creation of highly customized scFvs, boasting enhanced pharmacokinetic traits, thus greatly enhancing their clinical significance.
References:
Huston, J. S., Levinson, D., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences, 85(16), 5879-5883. https://doi.org/10.1073/pnas.85.16.5879
Cheadle, C., Hook, L. E., Givol, D., & Ricca, G. A. (1992). Cloning and expression of the variable regions of mouse myeloma protein MOPC315 in E. Coli: Recovery of active FV fragments. Molecular Immunology, 29(1), 21-30. https://doi.org/10.1016/0161-5890(92)90152-N
María, R., Irene, E., Fernando, L., & Alfredo, A. (2022). Single-Chain Fragment Variable: Recent Progress in Cancer Diagnosis and Therapy. Cancers, 14(17), 4206. https://doi.org/10.3390/cancers14174206
Antibodies are versatile molecules that perform a range of effector functions, many of which engage different arms of the immune system. Their modes of action extend beyond simple antigen binding, enabling the activation of various immune mechanisms that lead to pathogen neutralization and clearance. These functions include blocking molecular interactions, activating the complement system, and linking the humoral immune response to cellular immune responses via Fc receptor engagement.
In today’s competitive biotech landscape, intellectual property (IP) protection has become an essential pillar in fostering innovation and collaboration across drug discovery and development. By offering clear IP terms and no royalty fees,pharmaceutical companies and research institutes
In addition to isotypes and subtypes, antibodies exhibit genetic variation known as allotypes, which are polymorphic epitopes on immunoglobulins. These allotypic differences arise from allelic variations in immunoglobulin genes, causing certain antibody subtypes to differ between individuals or ethnic groups. The presence of these polymorphic forms can influence immune responses, particularly when an individual is exposed to a non-self allotype, potentially triggering an anti-allotype immune reaction.
In mammals, antibodies are classified into five major isotypes: IgA, IgD, IgE, IgG, and IgM. Each isotype is defined by the heavy chain it contains: alpha (IgA), delta (IgD), epsilon (IgE), gamma (IgG), or mu (IgM). These structural differences in the heavy chains determine the antibody's function, tissue localization, and role in the immune response. Furthermore, antibody light chains fall into two classes—kappa and lambda—with kappa being more common, though both exhibit similar functions despite differences in sequence.
